蜂斗菜属——泽勒：编号ZE 339。

Petasites--Zeller: ZE 339.

出版信息

Drugs R D. 2003;4(6):378-9. doi: 10.2165/00126839-200304060-00011.

DOI:10.2165/00126839-200304060-00011

Abstract

The Swiss company Zeller is developing an extract of the plant Petasites hybridus (butterbur) as an antiallergic agent. Petasites hybridus extracts have been known for some time to have therapeutic properties. Zeller's extract is codenamed ZE 339. In in vitro studies, ZE 339 inhibited cysteinyl-leukotriene synthesis in eosinophils and leukotriene B4 synthesis in neutrophils. In mid-2003, ZE 339 was approved, and launched, in Switzerland as Tesalin for the treatment of seasonal allergic rhinitis as a prescription-only product. Tesalin is available as film-coated tablets. Zeller has stated that hepatotoxicity cannot be totally excluded as a possible adverse reaction to Tesalin.

摘要

瑞士的泽勒公司正在研发一种名为蜂斗菜（Petasites hybridus）的植物提取物作为抗过敏剂。一段时间以来，人们已经知道蜂斗菜提取物具有治疗特性。泽勒公司的提取物代号为ZE 339。在体外研究中，ZE 339抑制嗜酸性粒细胞中半胱氨酰白三烯的合成以及中性粒细胞中白三烯B4的合成。2003年年中，ZE 339在瑞士获批并作为仅凭处方使用的产品泰萨林（Tesalin）上市，用于治疗季节性过敏性鼻炎。泰萨林为薄膜包衣片。泽勒公司表示，不能完全排除泰萨林可能产生肝毒性这一不良反应。